vs

Side-by-side financial comparison of MADRIGAL PHARMACEUTICALS, INC. (MDGL) and UiPath, Inc. (PATH). Click either name above to swap in a different company.

UiPath, Inc. is the larger business by last-quarter revenue ($411.1M vs $321.1M, roughly 1.3× MADRIGAL PHARMACEUTICALS, INC.). UiPath, Inc. runs the higher net margin — 48.4% vs -18.2%, a 66.6% gap on every dollar of revenue. On growth, MADRIGAL PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (210.8% vs 15.9%). UiPath, Inc. produced more free cash flow last quarter ($25.1M vs $-133.8M).

Intercept Pharmaceuticals, Inc. is an American biopharmaceutical company incorporated in 2002, focusing on the development of novel synthetic bile acid analogs to treat chronic liver diseases, such as primary biliary cirrhosis (PBC) now called primary biliary cholangitis, non-alcoholic fatty liver disease, cirrhosis, portal hypertension, primary sclerosing cholangitis and also the intestinal disorder, bile acid diarrhea.

UiPath Inc. is a global software company that develops artificial intelligence (AI) and agentic automation and orchestration software. The company's software enables the building and orchestration of AI agents to automate complex processes and workflows.

MDGL vs PATH — Head-to-Head

Bigger by revenue
PATH
PATH
1.3× larger
PATH
$411.1M
$321.1M
MDGL
Growing faster (revenue YoY)
MDGL
MDGL
+194.8% gap
MDGL
210.8%
15.9%
PATH
Higher net margin
PATH
PATH
66.6% more per $
PATH
48.4%
-18.2%
MDGL
More free cash flow
PATH
PATH
$159.0M more FCF
PATH
$25.1M
$-133.8M
MDGL

Income Statement — Q4 FY2025 vs Q3 FY2026

Metric
MDGL
MDGL
PATH
PATH
Revenue
$321.1M
$411.1M
Net Profit
$-58.6M
$198.8M
Gross Margin
83.3%
Operating Margin
-18.6%
3.2%
Net Margin
-18.2%
48.4%
Revenue YoY
210.8%
15.9%
Net Profit YoY
1.4%
1966.2%
EPS (diluted)
$-2.55
$0.37

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
MDGL
MDGL
PATH
PATH
Q4 25
$321.1M
$411.1M
Q3 25
$287.3M
$361.7M
Q2 25
$212.8M
$356.6M
Q1 25
$137.3M
$423.6M
Q4 24
$103.3M
$354.7M
Q3 24
$62.2M
$316.3M
Q2 24
$335.1M
Q1 24
$0
$405.3M
Net Profit
MDGL
MDGL
PATH
PATH
Q4 25
$-58.6M
$198.8M
Q3 25
$-114.2M
$1.6M
Q2 25
$-42.3M
$-22.6M
Q1 25
$-73.2M
$51.8M
Q4 24
$-59.4M
$-10.7M
Q3 24
$-107.0M
$-86.1M
Q2 24
$-28.7M
Q1 24
$-147.5M
$33.9M
Gross Margin
MDGL
MDGL
PATH
PATH
Q4 25
83.3%
Q3 25
82.2%
Q2 25
82.1%
Q1 25
96.7%
84.8%
Q4 24
82.0%
Q3 24
80.0%
Q2 24
83.5%
Q1 24
86.8%
Operating Margin
MDGL
MDGL
PATH
PATH
Q4 25
-18.6%
3.2%
Q3 25
-39.7%
-5.6%
Q2 25
-22.2%
-4.6%
Q1 25
-57.8%
7.9%
Q4 24
-64.8%
-12.2%
Q3 24
-187.1%
-32.7%
Q2 24
-14.8%
Q1 24
3.7%
Net Margin
MDGL
MDGL
PATH
PATH
Q4 25
-18.2%
48.4%
Q3 25
-39.8%
0.4%
Q2 25
-19.9%
-6.3%
Q1 25
-53.4%
12.2%
Q4 24
-57.5%
-3.0%
Q3 24
-172.0%
-27.2%
Q2 24
-8.6%
Q1 24
8.4%
EPS (diluted)
MDGL
MDGL
PATH
PATH
Q4 25
$-2.55
$0.37
Q3 25
$-5.08
$0.00
Q2 25
$-1.90
$-0.04
Q1 25
$-3.32
$0.09
Q4 24
$-2.50
$-0.02
Q3 24
$-4.92
$-0.15
Q2 24
$-0.05
Q1 24
$-7.38
$0.07

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
MDGL
MDGL
PATH
PATH
Cash + ST InvestmentsLiquidity on hand
$198.7M
$1.4B
Total DebtLower is stronger
$339.9M
Stockholders' EquityBook value
$602.7M
$1.9B
Total Assets
$1.3B
$2.9B
Debt / EquityLower = less leverage
0.56×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
MDGL
MDGL
PATH
PATH
Q4 25
$198.7M
$1.4B
Q3 25
$295.7M
$1.4B
Q2 25
$186.2M
$1.6B
Q1 25
$183.6M
$1.6B
Q4 24
$100.0M
$1.6B
Q3 24
$232.7M
$1.7B
Q2 24
$1.9B
Q1 24
$622.5M
$1.9B
Total Debt
MDGL
MDGL
PATH
PATH
Q4 25
$339.9M
Q3 25
$339.8M
Q2 25
$118.4M
Q1 25
$118.0M
Q4 24
$117.6M
Q3 24
$117.1M
Q2 24
Q1 24
$116.1M
Stockholders' Equity
MDGL
MDGL
PATH
PATH
Q4 25
$602.7M
$1.9B
Q3 25
$625.7M
$1.7B
Q2 25
$696.0M
$1.7B
Q1 25
$710.6M
$1.8B
Q4 24
$754.4M
$1.7B
Q3 24
$777.2M
$1.8B
Q2 24
$2.0B
Q1 24
$850.8M
$2.0B
Total Assets
MDGL
MDGL
PATH
PATH
Q4 25
$1.3B
$2.9B
Q3 25
$1.4B
$2.6B
Q2 25
$1.0B
$2.6B
Q1 25
$996.6M
$2.9B
Q4 24
$1.0B
$2.7B
Q3 24
$1.1B
$2.7B
Q2 24
$2.8B
Q1 24
$1.1B
$3.0B
Debt / Equity
MDGL
MDGL
PATH
PATH
Q4 25
0.56×
Q3 25
0.54×
Q2 25
0.17×
Q1 25
0.17×
Q4 24
0.16×
Q3 24
0.15×
Q2 24
Q1 24
0.14×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
MDGL
MDGL
PATH
PATH
Operating Cash FlowLast quarter
$-133.5M
$28.3M
Free Cash FlowOCF − Capex
$-133.8M
$25.1M
FCF MarginFCF / Revenue
-41.7%
6.1%
Capex IntensityCapex / Revenue
0.1%
0.8%
Cash ConversionOCF / Net Profit
0.14×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
MDGL
MDGL
PATH
PATH
Q4 25
$-133.5M
$28.3M
Q3 25
$79.8M
$41.6M
Q2 25
$-47.1M
$119.0M
Q1 25
$-88.9M
$146.1M
Q4 24
$-104.5M
$28.1M
Q3 24
$-67.0M
$46.4M
Q2 24
$100.0M
Q1 24
$-149.2M
$145.6M
Free Cash Flow
MDGL
MDGL
PATH
PATH
Q4 25
$-133.8M
$25.1M
Q3 25
$79.0M
Q2 25
$106.2M
Q1 25
$138.7M
Q4 24
$-104.7M
$23.2M
Q3 24
$-67.8M
$45.0M
Q2 24
$98.8M
Q1 24
$-149.5M
$141.8M
FCF Margin
MDGL
MDGL
PATH
PATH
Q4 25
-41.7%
6.1%
Q3 25
27.5%
Q2 25
29.8%
Q1 25
32.7%
Q4 24
-101.3%
6.5%
Q3 24
-109.0%
14.2%
Q2 24
29.5%
Q1 24
35.0%
Capex Intensity
MDGL
MDGL
PATH
PATH
Q4 25
0.1%
0.8%
Q3 25
0.3%
0.0%
Q2 25
0.0%
3.6%
Q1 25
0.0%
1.7%
Q4 24
0.2%
1.4%
Q3 24
1.3%
0.4%
Q2 24
0.4%
Q1 24
0.9%
Cash Conversion
MDGL
MDGL
PATH
PATH
Q4 25
0.14×
Q3 25
26.25×
Q2 25
Q1 25
2.82×
Q4 24
Q3 24
Q2 24
Q1 24
4.29×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

MDGL
MDGL

Rebates Customer Fees Credits Co Pay Assistance And Other$208.5M65%
Other$76.0M24%
Chargebacks Discounts For Prompt Pay And Other Allowances$36.6M11%

PATH
PATH

Subscription Services$247.6M60%
License$150.0M36%
Professional Services And Other$13.5M3%

Related Comparisons